引用本文
  • 陈安妮,范成龙,范国荣,李琴.新型口服抗凝药的药物基因组学研究进展[J].第二军医大学学报,2020,41(5):558-563    [点击复制]
  • CHEN An-ni,FAN Cheng-long,FAN Guo-rong,LI Qin.Advances in pharmacogenomics of new oral anticoagulants[J].Acad J Sec Mil Med Univ,2020,41(5):558-563   [点击复制]
【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 92次   下载 78 本文二维码信息
码上扫一扫!
新型口服抗凝药的药物基因组学研究进展
陈安妮1,2,范成龙1,范国荣1,李琴1*
0
(1. 上海交通大学附属第一人民医院临床药学室, 上海 200080;
2. 海军军医大学(第二军医大学)东方肝胆外科医院药材科, 上海 200438
*通信作者)
摘要:
新型口服抗凝药(NOAC)在心脑血管血栓疾病的防治中发挥了重要作用。由于参与NOAC体内过程的转运体和代谢酶的基因多态性,不同个体口服相同剂量的NOAC后,其体内药代动力学参数存在差异。相对于药物转运体,药物代谢酶的基因多态性对NOAC的药代动力学性质影响较大,但目前相关研究较少。本文分析总结了基因多态性对NOAC药代动力学性质的影响。
关键词:  新型口服抗凝药  药物基因组学  转运系统  代谢酶类  药代动力学  基因多态性
DOI:10.16781/j.0258-879x.2020.05.0558
投稿时间:2019-09-16修订日期:2019-10-25
基金项目:上海交通大学医工交叉研究基金面上项目(YG2017MS29).
Advances in pharmacogenomics of new oral anticoagulants
CHEN An-ni1,2,FAN Cheng-long1,FAN Guo-rong1,LI Qin1*
(1. Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China;
2. Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University(Second Military Medical University), Shanghai 200438, China
*Corresponding author)
Abstract:
Novel oral anticoagulants (NOACs) play an important role in the prevention and treatment of cardiovascular and cerebrovascular thrombosis. Different individuals have different pharmacokinetic parameters in vivo after taking the same dose of NOACs, which may be related to gene polymorphisms of transporters and metabolic enzymes involved in the in vivo process of NOACs. Compared with drug transporters, gene polymorphisms of drug metabolizing enzymes have a greater impact on the pharmacokinetic properties of NOACs, but there have been few related studies up to now. In this paper we summarized the effects of gene polymorphisms on the pharmacokinetic properties of NOACs.
Key words:  new oral anticoagulants  pharmacogenomics  transport system  metabolic enzymes  pharmacokinetics  gene polymorphisms